Is apolipoprotein A-V a potent modulator of HDL and VLDL components in preadolescent children?
It was suggested that apoA-V is a potent modulator of HDL and VLDL components in preadolescent children.
Although detection of asymptomatic recurrences gives a lead time bias of 8 to 10 months, mode of treatment and overall survival duration are not greatly affected by this earlier detection. Disease-free interval appears to be the most important determinant of survival. Screening for asymptomatic recurrences in patients who have had lung cancer is unlikely to be cost-effective. Frequent follow-up and extensive radiologic evaluation of patients after operation for lung cancer are probably unnecessary.